Professional Documents
Culture Documents
Cancer Pancreatico
Cancer Pancreatico
4
w
k
,
d
i
v
i
d
e
d
i
n
t
w
o
d
a
i
l
y
d
o
s
e
s
N
e
u
t
r
o
p
e
n
i
a
(
2
3
%
)
B
e
r
n
h
a
r
d
e
t
a
l
.
7
4
G
e
m
c
i
t
a
b
i
n
e
p
l
u
s
e
r
l
o
t
i
n
i
b
E
r
l
o
t
i
n
i
b
i
s
a
s
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
o
f
t
h
e
e
p
i
d
e
r
m
a
l
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
G
e
m
c
i
t
a
b
i
n
e
:
1
0
0
0
m
g
/
m
2
g
i
v
e
n
a
s
3
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
,
e
i
t
h
e
r
w
e
e
k
l
y
f
o
r
7
w
k
f
o
l
l
o
w
e
d
b
y
1
w
k
r
e
s
t
,
t
h
e
n
w
e
e
k
l
y
f
o
r
3
o
f
e
v
e
r
y
4
w
k
,
o
r
w
e
e
k
l
y
f
o
r
3
o
f
e
v
e
r
y
4
w
k
;
p
l
u
s
e
r
l
o
t
i
n
i
b
:
1
0
0
m
g
/
d
a
y
o
r
a
l
l
y
d
a
i
l
y
N
e
u
t
r
o
p
e
n
i
a
(
2
4
%
)
,
i
n
f
e
c
t
i
o
n
(
1
7
%
)
,
f
a
t
i
g
u
e
(
1
5
%
)
,
e
l
e
v
a
t
e
d
A
S
T
l
e
v
e
l
(
1
1
%
)
,
t
h
r
o
m
b
o
c
y
t
o
p
e
n
i
a
(
1
0
%
)
M
o
o
r
e
e
t
a
l
.
6
7
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.
Medical Progress
n engl j med 362;17 nejm.org april 29, 2010
1613
S
e
c
o
n
d
-
l
i
n
e
t
h
e
r
a
p
y
M
o
d
i
f
i
e
d
F
O
L
F
O
X
(
c
o
m
b
i
n
a
t
i
o
n
r
e
g
i
m
e
n
i
n
c
l
u
d
i
n
g
o
x
a
l
i
p
l
a
t
i
n
,
f
l
u
o
r
o
u
r
a
c
i
l
,
a
n
d
l
e
u
c
o
v
o
r
i
n
)
F
l
u
o
r
o
u
r
a
c
i
l
i
s
a
n
i
n
h
i
b
i
t
o
r
o
f
t
h
y
m
i
d
i
l
a
t
e
s
y
n
t
h
e
t
a
s
e
,
a
n
d
l
e
u
c
o
v
o
r
i
n
p
o
t
e
n
t
i
-
a
t
e
s
t
h
e
i
n
h
i
b
i
t
i
o
n
o
f
t
h
y
m
i
d
i
l
a
t
e
s
y
n
t
h
e
t
a
s
e
b
y
f
l
u
o
r
o
u
r
a
c
i
l
O
x
a
l
i
p
l
a
t
i
n
:
8
5
m
g
/
m
2
g
i
v
e
n
a
s
1
2
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
e
v
e
r
y
o
t
h
e
r
w
k
;
l
e
u
c
o
v
o
r
-
i
n
:
4
0
0
m
g
/
m
2
o
n
d
a
y
1
,
e
v
e
r
y
o
t
h
e
r
w
k
;
a
n
d
f
l
u
o
r
o
u
r
a
c
i
l
:
2
0
0
0
m
g
/
m
2
g
i
v
e
n
a
s
4
6
-
h
r
i
n
f
u
s
i
o
n
e
v
e
r
y
o
t
h
e
r
w
k
N
e
u
t
r
o
p
e
n
i
a
(
2
0
%
)
,
a
s
t
h
e
n
i
a
(
1
3
%
)
,
v
o
m
i
t
i
n
g
(
1
0
%
)
L
i
a
n
d
S
a
i
f
7
5
M
o
d
i
f
i
e
d
F
O
L
F
I
R
I
.
3
(
c
o
m
b
i
n
a
t
i
o
n
r
e
g
i
m
e
n
o
f
i
r
i
n
o
t
e
c
a
n
w
i
t
h
f
l
u
o
r
o
u
r
a
c
i
l
a
n
d
l
e
u
c
o
v
o
r
i
n
)
F
l
u
o
r
o
u
r
a
c
i
l
i
s
a
n
i
n
h
i
b
i
t
o
r
o
f
t
h
y
m
i
d
i
l
a
t
e
s
y
n
t
h
e
t
a
s
e
,
a
n
d
i
r
i
n
o
t
e
c
a
n
i
s
a
t
o
p
o
-
i
s
o
m
e
r
a
s
e
I
i
n
h
i
b
i
t
o
r
;
l
e
u
c
o
v
o
r
i
n
p
o
-
t
e
n
t
i
a
t
e
s
t
h
e
i
n
h
i
b
i
t
i
o
n
o
f
t
h
y
m
i
d
i
l
a
t
e
s
y
n
t
h
e
t
a
s
e
b
y
f
l
u
o
r
o
u
r
a
c
i
l
I
r
i
n
o
t
e
c
a
n
:
7
0
m
g
/
m
2
g
i
v
e
n
a
s
6
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
o
n
d
a
y
1
;
l
e
u
c
o
v
o
r
i
n
:
4
0
0
m
g
/
m
2
g
i
v
e
n
a
s
g
i
v
e
n
a
s
1
2
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
o
n
d
a
y
1
;
a
n
d
f
l
u
o
r
o
u
r
a
c
i
l
:
2
0
0
0
m
g
/
m
2
g
i
v
e
n
a
s
4
6
-
h
r
I
V
i
n
f
u
-
s
i
o
n
o
n
d
a
y
1
;
a
n
d
i
r
i
n
o
t
e
c
a
n
:
7
0
m
g
/
m
g
2
g
i
v
e
n
a
s
6
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
a
t
t
h
e
e
n
d
o
f
t
h
e
i
n
f
u
s
i
o
n
o
f
f
l
u
o
r
o
u
r
a
-
c
i
l
,
e
v
e
r
y
2
w
k
N
e
u
t
r
o
p
e
n
i
a
(
2
2
%
)
,
v
o
m
i
t
i
n
g
(
1
0
%
)
L
i
a
n
d
S
a
i
f
7
5
O
x
a
l
i
p
l
a
t
i
n
p
l
u
s
c
a
p
e
c
i
t
a
b
i
n
e
O
x
a
l
i
p
l
a
t
i
n
i
s
a
d
i
a
m
i
n
o
c
y
c
l
o
h
e
x
a
n
o
p
l
a
t
i
n
u
m
a
n
a
l
o
g
u
e
t
h
a
t
b
i
n
d
s
a
n
d
a
l
-
k
y
l
a
t
e
s
D
N
A
;
c
a
p
e
c
i
t
a
b
i
n
e
i
s
c
o
n
v
e
r
t
-
e
d
i
n
t
h
e
t
u
m
o
r
t
o
f
l
u
o
r
o
u
r
a
c
i
l
a
n
d
i
n
h
i
b
i
t
s
t
h
y
m
i
d
i
l
a
t
e
s
y
n
t
h
e
t
a
s
e
O
x
a
l
i
p
l
a
t
i
n
:
1
3
0
m
g
/
m
2
g
i
v
e
n
a
s
1
2
0
-
m
i
n
I
V
i
n
f
u
s
i
o
n
e
v
e
r
y
3
w
k
;
a
n
d
c
a
p
e
c
i
t
a
b
i
n
e
:
2
0
0
0
m
g
/
m
2
d
a
i
l
y
,
o
r
a
l
l
y
f
o
r
1
4
d
a
y
s
e
v
e
r
y
3
4
w
k
,
d
i
v
i
d
e
d
i
n
t
w
o
d
a
i
l
y
d
o
s
e
s
O
x
a
l
i
p
l
a
t
i
n
:
f
a
t
i
g
u
e
(
1
3
%
)
,
d
i
a
r
r
h
e
a
(
5
%
)
,
v
o
m
i
t
i
n
g
(
3
%
)
;
c
a
p
e
c
i
t
a
b
i
n
e
:
h
a
n
d
f
o
o
t
s
y
n
d
r
o
m
e
(
3
%
)
,
a
b
d
o
m
i
-
n
a
l
p
a
i
n
(
3
%
)
X
i
o
n
g
e
t
a
l
.
6
9
C
a
p
e
c
i
t
a
b
i
n
e
p
l
u
s
e
r
l
o
t
i
n
i
b
C
a
p
e
c
i
t
a
b
i
n
e
i
s
c
o
n
v
e
r
t
e
d
i
n
t
h
e
t
u
m
o
r
t
o
f
l
u
o
r
o
u
r
a
c
i
l
a
n
d
i
n
h
i
b
i
t
s
t
h
y
m
i
d
i
-
l
a
t
e
s
y
n
t
h
e
t
a
s
e
;
e
r
l
o
t
i
n
i
b
i
s
a
s
m
a
l
l
-
m
o
l
e
c
u
l
a
r
i
n
h
i
b
i
t
o
r
o
f
t
h
e
e
p
i
d
e
r
m
a
l
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
C
a
p
e
c
i
t
a
b
i
n
e
:
2
0
0
0
m
g
/
m
2
d
a
i
l
y
,
o
r
a
l
l
y
f
o
r
1
4
d
a
y
s
e
v
e
r
y
3
4
w
k
,
d
i
v
i
d
e
d
i
n
t
w
o
d
a
i
l
y
d
o
s
e
s
;
a
n
d
e
r
l
o
t
i
n
i
b
:
1
5
0
m
g
o
r
a
l
l
y
d
a
i
l
y
C
a
p
e
c
i
t
a
b
i
n
e
:
d
i
a
r
r
h
e
a
(
1
7
%
)
,
r
a
s
h
(
1
3
%
)
,
h
a
n
d
f
o
o
t
s
y
n
d
r
o
m
e
(
1
3
%
)
,
m
u
c
o
s
i
-
t
i
s
(
1
0
%
)
;
e
r
l
o
t
i
n
i
b
:
f
a
t
i
g
u
e
(
3
%
)
,
e
l
e
-
v
a
t
e
d
b
i
l
i
r
u
b
i
n
l
e
v
e
l
(
3
%
)
,
e
l
e
v
a
t
e
d
a
l
k
a
l
i
n
e
p
h
o
s
p
h
a
t
a
s
e
l
e
v
e
l
(
3
%
)
K
u
l
k
e
e
t
a
l
.
7
0
*
A
S
T
d
e
n
o
t
e
s
a
s
p
a
r
t
a
t
e
a
m
i
n
o
t
r
a
n
s
f
e
r
a
s
e
;
d
F
d
C
d
i
f
l
u
o
r
o
d
e
o
x
y
c
y
t
i
d
i
n
e
;
F
O
L
F
I
R
I
.
3
r
e
g
i
m
e
n
o
f
f
l
u
o
r
o
u
r
a
c
i
l
,
l
e
u
c
o
v
o
r
i
n
,
a
n
d
i
r
i
n
o
t
e
c
a
n
;
F
O
L
F
O
X
r
e
g
i
m
e
n
o
f
f
o
l
i
n
i
c
a
c
i
d
,
f
l
u
o
r
o
u
r
a
c
i
l
,
a
n
d
o
x
a
l
i
p
l
a
t
i
n
;
a
n
d
I
V
i
n
t
r
a
v
e
n
o
u
s
.
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.
The new engl and journal o f medicine
n engl j med 362;17 nejm.org april 29, 2010
1614
T
a
b
l
e
3
.
S
e
l
e
c
t
e
d
S
t
r
a
t
e
g
i
c
T
a
r
g
e
t
s
i
n
P
a
n
c
r
e
a
t
i
c
C
a
n
c
e
r
.
*
T
a
r
g
e
t
A
g
e
n
t
D
r
u
g
C
l
a
s
s
M
e
c
h
a
n
i
s
m
o
f
A
c
t
i
o
n
T
r
i
a
l
P
h
a
s
e
R
e
f
e
r
e
n
c
e
S
P
A
R
C
N
a
n
o
p
a
r
t
i
c
l
e
a
l
b
u
m
i
n
-
b
o
u
n
d
p
a
c
l
i
t
a
x
e
l
C
y
t
o
t
o
x
i
c
a
g
e
n
t
S
P
A
R
C
,
e
x
p
r
e
s
s
e
d
i
n
c
a
n
c
e
r
c
e
l
l
s
a
n
d
s
t
r
o
m
a
i
n
t
h
e
p
a
n
c
r
e
a
s
,
b
i
n
d
s
n
a
n
o
p
a
r
t
i
c
l
e
a
l
b
u
m
i
n
-
b
o
u
n
d
p
a
c
l
i
t
a
x
e
l
,
i
n
c
r
e
a
s
i
n
g
l
o
c
a
l
d
r
u
g
d
e
l
i
v
e
r
y
3
L
i
a
n
d
S
a
i
f
7
5
I
G
F
-
I
R
M
K
0
6
4
6
,
A
M
G
4
7
9
,
R
1
5
0
7
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
I
n
h
i
b
i
t
s
l
i
g
a
n
d
b
i
n
d
i
n
g
a
c
t
i
v
a
t
i
o
n
o
f
t
h
e
I
G
F
-
I
R
a
n
d
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
3
H
e
w
i
s
h
e
t
a
l
.
7
8
D
e
a
t
h
r
e
c
e
p
t
o
r
A
M
G
6
5
5
,
C
S
1
0
0
8
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
A
g
o
n
i
s
t
a
n
t
i
b
o
d
i
e
s
t
o
m
e
m
b
r
a
n
e
d
e
a
t
h
r
e
c
e
p
t
o
r
s
i
n
d
u
c
e
a
p
o
p
t
o
s
i
s
2
L
i
a
n
d
S
a
i
f
,
7
5
D
e
r
o
s
i
e
r
e
t
a
l
.
7
9
M
u
c
i
n
-
1
9
0
Y
-
h
P
A
M
4
R
a
d
i
o
i
m
m
u
n
o
c
o
n
j
u
g
a
t
e
T
a
r
g
e
t
s
m
u
c
i
n
-
1
e
x
p
r
e
s
s
e
d
i
n
p
a
n
c
r
e
a
t
i
c
-
c
a
n
c
e
r
c
e
l
l
s
a
n
d
d
e
l
i
v
e
r
s
r
a
d
i
a
t
i
o
n
l
o
a
d
1
2
G
o
l
d
e
t
a
l
.
8
0
H
e
d
g
e
h
o
g
p
a
t
h
w
a
y
G
D
C
-
0
4
4
9
,
I
P
I
-
9
2
6
S
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
I
n
h
i
b
i
t
s
s
m
o
o
t
h
e
n
e
d
r
e
c
e
p
t
o
r
,
r
e
s
u
l
t
i
n
g
i
n
i
n
h
i
b
i
t
i
o
n
o
f
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
;
t
a
r
g
e
t
s
c
a
n
c
e
r
s
t
r
o
m
a
a
n
d
c
a
n
c
e
r
s
t
e
m
c
e
l
l
s
i
n
t
h
e
p
a
n
c
r
e
a
s
1
O
l
i
v
e
e
t
a
l
.
,
2
9
J
i
m
e
n
o
e
t
a
l
.
3
2
c
-
k
i
t
,
P
D
G
F
R
,
F
G
F
R
M
a
s
i
t
i
n
i
b
S
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
M
u
l
t
i
k
i
n
a
s
e
i
n
h
i
b
i
t
o
r
t
a
r
g
e
t
s
c
-
k
i
t
,
P
D
G
F
R
,
a
n
d
F
G
F
R
3
a
n
d
a
f
f
e
c
t
s
t
h
e
F
A
K
p
a
t
h
w
a
y
;
m
a
s
i
t
i
n
i
b
w
a
s
s
h
o
w
n
t
o
e
n
h
a
n
c
e
t
h
e
a
n
t
i
p
r
o
l
i
f
e
r
a
t
i
v
e
e
f
f
e
c
t
s
o
f
g
e
m
c
i
t
a
b
i
n
e
i
n
p
r
e
c
l
i
n
i
c
a
l
s
t
u
d
i
e
s
3
L
i
a
n
d
S
a
i
f
7
5
M
E
K
A
Z
D
6
2
4
4
S
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
T
a
r
g
e
t
s
a
n
d
i
n
h
i
b
i
t
s
M
E
K
,
d
e
c
r
e
a
s
i
n
g
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
2
C
h
u
n
g
e
t
a
l
.
8
1
S
r
c
A
Z
D
0
5
3
0
,
d
a
s
a
t
i
n
i
b
S
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
T
a
r
g
e
t
s
a
n
d
i
n
h
i
b
i
t
s
S
r
c
k
i
n
a
s
e
,
r
e
s
u
l
t
i
n
g
i
n
i
n
h
i
b
i
t
i
o
n
o
f
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
a
n
d
i
n
v
a
s
i
o
n
2
R
a
j
e
s
h
k
u
m
a
r
e
t
a
l
.
7
7
R
A
S
S
a
r
i
l
a
s
i
b
S
m
a
l
l
-
m
o
l
e
c
u
l
e
i
n
h
i
b
i
t
o
r
D
i
s
l
o
d
g
e
s
a
l
l
f
o
r
m
s
o
f
R
A
S
f
r
o
m
t
h
e
p
l
a
s
m
a
m
e
m
b
r
a
n
e
,
i
n
h
i
b
i
t
i
n
g
R
A
S
s
i
g
n
a
l
i
n
g
2
H
a
k
l
a
i
e
t
a
l
.
8
2
P
S
C
A
A
G
S
-
1
C
4
D
4
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
B
i
n
d
s
m
e
m
b
r
a
n
e
P
S
C
A
;
s
p
e
c
i
f
i
c
m
e
c
h
a
n
i
s
m
s
o
f
c
e
l
l
k
i
l
l
i
n
g
u
n
d
e
t
e
r
m
i
n
e
d
2
W
e
n
t
e
e
t
a
l
.
8
3
M
e
s
o
t
h
e
l
i
n
M
O
R
A
b
-
0
0
9
M
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
B
i
n
d
s
m
e
m
b
r
a
n
e
m
e
s
o
t
h
e
l
i
n
;
s
p
e
c
i
f
i
c
m
e
c
h
a
n
i
s
m
s
o
f
c
e
l
l
k
i
l
l
i
n
g
u
n
d
e
t
e
r
m
i
n
e
d
2
H
a
s
s
a
n
e
t
a
l
.
8
4
T
N
F
-
T
N
F
e
r
a
d
e
G
e
n
e
t
h
e
r
a
p
y
A
d
e
n
o
v
i
r
a
l
g
e
n
e
t
h
e
r
a
p
y
i
n
c
r
e
a
s
e
s
i
n
t
r
a
t
u
m
o
r
a
l
c
o
n
c
e
n
t
r
a
t
i
o
n
o
f
T
N
F
-
3
M
u
r
u
g
e
s
a
n
e
t
a
l
.
8
5
*
T
h
e
a
b
b
r
e
v
i
a
t
i
o
n
c
-
k
i
t
d
e
n
o
t
e
s
s
t
e
m
-
c
e
l
l
f
a
c
t
o
r
r
e
c
e
p
t
o
r
;
F
A
K
f
o
c
a
l
a
d
h
e
s
i
o
n
k
i
n
a
s
e
;
F
G
F
R
f
i
b
r
o
b
l
a
s
t
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
;
I
G
F
-
I
R
t
y
p
e
I
i
n
s
u
l
i
n
-
l
i
k
e
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
;
M
E
K
m
i
t
o
g
e
n
-
a
c
t
i
v
a
t
e
d
p
r
o
t
e
i
n
k
i
n
a
s
e
e
x
t
r
a
c
e
l
l
u
l
a
r
-
s
i
g
n
a
l
r
e
g
u
l
a
t
e
d
k
i
n
a
s
e
,
P
D
G
F
R
p
l
a
t
e
l
e
t
-
d
e
r
i
v
e
d
g
r
o
w
t
h
f
a
c
t
o
r
;
P
S
C
A
p
r
o
s
t
a
t
e
s
t
e
m
-
c
e
l
l
a
n
t
i
g
e
n
;
S
P
A
R
C
s
e
c
r
e
t
e
d
p
r
o
t
e
i
n
,
a
c
i
d
i
c
,
c
y
s
t
e
i
n
e
-
r
i
c
h
;
a
n
d
T
N
F
-
t
u
m
o
r
n
e
c
r
o
s
i
s
f
a
c
t
o
r
.
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.
Medical Progress
n engl j med 362;17 nejm.org april 29, 2010
1615
tients who are ambulatory and minimally symp-
tomatic).
69,70
Table 2 lists commonly used first-line
and second-line therapeutic regimens.
Future Directions
There is much room for improvement in all as-
pects of treatment for pancreatic cancer. Screen-
ing of high-risk persons by means of either in-
novative imaging methods or measurements of
serum biomarkers for early diagnosis is criti-
cal.
42,43,76
A better understanding of the biology
of pancreatic cancer is opening new avenues for
treatment, and an increasing number of new tar-
geted agents are in clinical development (Table 3).
These agents include small-molecule inhibitors of
oncogenes and signaling pathways such as RAS,
Src, and MEK, monoclonal antibodies targeting
cell-membrane proteins such as mesothelin and
the so-called death receptors, and new nanotech-
nology and adenoviral agents. The recognition
that the tumor microenvironment and cancer
stem cells are critical components of pancreatic
cancer has led to the development of agents, such
as the hedgehog inhibitors, that target these
components.
23,29,31,32
The availability of preclini-
cal models that recapitulate the complexity of
this disease will probably help in establishing
priorities and strategies for the development of
new treatments.
77,86
The complexity of the genome
of pancreatic cancer indicates that it is a hetero-
geneous cancer and that methods to individual-
ize therapy will be required.
11,87
Dr. Hidalgo reports receiving grant support from Roche and
Daichi; being the principal investigator and receiving grant sup-
port for clinical studies of nanoparticle albumin-bound paclitaxel
from American Biosciences, of erlotinib from Roche, of AGS-
1C4D4 from Agensys, and of MORAb-009 from Eisai; and receiv-
ing consulting fees from American Biosciences, OSIGenentech,
Merck, and Agensys. No other potential conflict of interest rele-
vant to this article was reported.
I thank Wells Messersmith and Anirban Maitra for critical
comments on an earlier version of the manuscript and Sofia
Perea for editorial assistance.
References
Jemal A, Siegel R, Ward E, et al. Can- 1.
cer statistics, 2008. CA Cancer J Clin
2008;58:71-96.
Li D, Xie K, Wolff R, Abbruzzese JL. 2.
Pancreatic cancer. Lancet 2004;363:1049-
57.
Hassan MM, Bondy ML, Wolff RA, et al. 3.
Risk factors for pancreatic cancer: case-
control study. Am J Gastroenterol 2007;
102:2696-707.
Batty GD, Kivimaki M, Morrison D, 4.
et al. Risk factors for pancreatic cancer
mortality: extended follow-up of the orig-
inal Whitehall Study. Cancer Epidemiol
Biomarkers Prev 2009;18:673-5.
Landi S. Genetic predisposition and 5.
environmental risk factors to pancreatic
cancer: a review of the literature. Mutat
Res 2009;681:299-307.
Lowenfels AB, Maisonneuve P. Epide- 6.
miology and risk factors for pancreatic
cancer. Best Pract Res Clin Gastroenterol
2006;20:197-209.
Genkinger JM, Spiegelman D, Ander- 7.
son KE, et al. Alcohol intake and pancre-
atic cancer risk: a pooled analysis of four-
teen cohort studies. Cancer Epidemiol
Biomarkers Prev 2009;18:765-76.
Wolpin BM, Chan AT, Hartge P, et al. 8.
ABO blood group and the risk of pancre-
atic cancer. J Natl Cancer Inst 2009;101:
424-31.
Shi C, Hruban RH, Klein AP. Familial 9.
pancreatic cancer. Arch Pathol Lab Med
2009;133:365-74.
Tersmette AC, Petersen GM, Offer- 10.
haus GJ, et al. Increased risk of incident
pancreatic cancer among first-degree rel-
atives of patients with familial pancreatic
cancer. Clin Cancer Res 2001;7:738-44.
Jones S, Zhang X, Parsons DW, et al. 11.
Core signaling pathways in human pan-
creatic cancers revealed by global genom-
ic analyses. Science 2008;321:1801-6.
Couch FJ, Johnson MR, Rabe KG, et al. 12.
The prevalence of BRCA2 mutations in
familial pancreatic cancer. Cancer Epide-
miol Biomarkers Prev 2007;16:342-6.
Jones S, Hruban RH, Kamiyama M, et 13.
al. Exomic sequencing identifies PALB2
as a pancreatic cancer susceptibility gene.
Science 2009;324:217.
Vogelstein B, Kinzler KW. Cancer 14.
genes and the pathways they control. Nat
Med 2004;10:789-99.
Hruban RH, Maitra A, Goggins M. 15.
Update on pancreatic intraepithelial neo-
plasia. Int J Clin Exp Pathol 2008;1:306-
16.
Feldmann G, Beaty R, Hruban RH, 16.
Maitra A. Molecular genetics of pancre-
atic intraepithelial neoplasia. J Hepatobil-
iary Pancreat Surg 2007;14:224-32.
Hingorani SR, Wang L, Multani AS, et 17.
al. Trp53R172H and KrasG12D cooperate
to promote chromosomal instability and
widely metastatic pancreatic ductal ade-
nocarcinoma in mice. Cancer Cell 2005;
7:469-83.
Guerra C, Schuhmacher AJ, Caamero 18.
M, et al. Chronic pancreatitis is essential
for induction of pancreatic ductal adeno-
carcinoma by K-Ras oncogenes in adult
mice. Cancer Cell 2007;11:291-302.
Bardeesy N, Aguirre AJ, Chu GC, et al. 19.
Both p16(Ink4a) and the p19(Arf )-p53
pathway constrain progression of pancre-
atic adenocarcinoma in the mouse. Proc
Natl Acad Sci U S A 2006;103:5947-52.
Takaori K. Current understanding of 20.
precursors to pancreatic cancer. J Hepato-
biliary Pancreat Surg 2007;14:217-23.
Maitra A, Hruban RH. Pancreatic can- 21.
cer. Annu Rev Pathol 2008;3:157-88.
Chu GC, Kimmelman AC, Hezel AF, 22.
DePinho RA. Stromal biology of pancre-
atic cancer. J Cell Biochem 2007;101:887-
907.
Mahadevan D, Von Hoff DD. Tumor- 23.
stroma interactions in pancreatic ductal
adenocarcinoma. Mol Cancer Ther 2007;
6:1186-97.
Masamune A, Shimosegawa T. Signal 24.
transduction in pancreatic stellate cells.
J Gastroenterol 2009;44:249-60.
Erkan M, Reiser-Erkan C, Michalski 25.
CW, et al. Cancer-stellate cell interactions
perpetuate the hypoxia-fibrosis cycle in
pancreatic ductal adenocarcinoma. Neo-
plasia 2009;11:497-508.
Zhang W, Erkan M, Abiatari I, et al. 26.
Expression of extracellular matrix metal-
loproteinase inducer (EMMPRIN/CD147)
in pancreatic neoplasm and pancreatic
stellate cells. Cancer Biol Ther 2007;6:218-
27.
Mukherjee P, Basu GD, Tinder TL, et al. 27.
Progression of pancreatic adenocarcino-
ma is significantly impeded with a com-
bination of vaccine and COX-2 inhibition.
J Immunol 2009;182:216-24.
Infante JR, Matsubayashi H, Sato N, et 28.
al. Peritumoral fibroblast SPARC expres-
sion and patient outcome with resectable
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.
The new engl and journal o f medicine
n engl j med 362;17 nejm.org april 29, 2010
1616
pancreatic adenocarcinoma. J Clin Oncol
2007;25:319-25.
Olive KP, Jacobetz MA, Davidson CJ, 29.
et al. Inhibition of Hedgehog signaling
enhances delivery of chemotherapy in a
mouse model of pancreatic cancer. Science
2009;324:1457-61.
Li C, Heidt DG, Dalerba P, et al. Iden- 30.
tification of pancreatic cancer stem cells.
Cancer Res 2007;67:1030-7.
Hermann PC, Huber SL, Herrler T, 31.
et al. Distinct populations of cancer stem
cells determine tumor growth and meta-
static activity in human pancreatic cancer.
Cell Stem Cell 2007;1:313-23.
Jimeno A, Feldmann G, Surez-Gau- 32.
thier A, et al. A direct pancreatic cancer
xenograft model as a platform for cancer
stem cell therapeutic development. Mol
Cancer Ther 2009;8:310-4.
Miura F, Takada T, Amano H, Yoshida 33.
M, Furui S, Takeshita K. Diagnosis of pan-
creatic cancer. HPB (Oxford) 2006;8:337-
42.
Karmazanovsky G, Fedorov V, Kubysh- 34.
kin V, Kotchatkov A. Pancreatic head can-
cer: accuracy of CT in determination of
resectability. Abdom Imaging 2005;30:
488-500.
Dumonceau JM, Vonlaufen A. Pancre- 35.
atic endoscopic retrograde cholangiopan-
creatography (ERCP). Endoscopy 2007;39:
124-30.
Mayo SC, Austin DF, Sheppard BC, 36.
Mori M, Shipley DK, Billingsley KG. Evolv-
ing preoperative evaluation of patients
with pancreatic cancer: does laparoscopy
have a role in the current era? J Am Coll
Surg 2009;208:87-95.
Harsha HC, Kandasamy K, Rangana- 37.
than P, et al. A compendium of potential
biomarkers of pancreatic cancer. PLoS
Med 2009;6(4):e1000046.
Berger AC, Garcia M Jr, Hoffman JP, 38.
et al. Postresection CA 19-9 predicts over-
all survival in patients with pancreatic
cancer treated with adjuvant chemoradia-
tion: a prospective validation by RTOG
9704. J Clin Oncol 2008;26:5918-22.
Hess V, Glimelius B, Grawe P, et al. 39.
CA 19-9 tumour-marker response to che-
motherapy in patients with advanced pan-
creatic cancer enrolled in a randomised
controlled trial. Lancet Oncol 2008;9:
132-8.
Ferrone CR, Finkelstein DM, Thayer 40.
SP, Muzikansky A, Fernandez-del Castillo
C, Warshaw AL. Perioperative CA19-9 levels
can predict stage and survival in patients
with resectable pancreatic adenocarcino-
ma. J Clin Oncol 2006;24:2897-902.
Ko AH, Hwang J, Venook AP, Abbruz- 41.
zese JL, Bergsland EK, Tempero MA. Se-
rum CA19-9 response as a surrogate for
clinical outcome in patients receiving
fixed-dose rate gemcitabine for advanced
pancreatic cancer. Br J Cancer 2005;93:
195-9.
Greenhalf W, Grocock C, Harcus M, 42.
Neoptolemos J. Screening of high-risk
families for pancreatic cancer. Pancrea-
tology 2009;9:215-22.
Larghi A, Verna EC, Lecca PG, Costa- 43.
magna G. Screening for pancreatic cancer
in high-risk individuals: a call for endo-
scopic ultrasound. Clin Cancer Res 2009;
15:1907-14.
Edge SB, Byrd DR, Compton CC, Fritz 44.
AG, Greene FL, Trotti A, eds. AJCC can-
cer staging manual. 7th ed. New York:
Springer, 2010.
Bilimoria KY, Bentrem DJ, Ko CY, et al. 45.
Validation of the 6th edition AJCC Pancre-
atic Cancer Staging System: report from
the National Cancer Database. Cancer
2007;110:738-44.
Pawlik TM, Laheru D, Hruban RH, et 46.
al. Evaluating the impact of a single-day
multidisciplinary clinic on the manage-
ment of pancreatic cancer. Ann Surg On-
col 2008;15:2081-8.
Katz MH, Wang H, Fleming JB, et al. 47.
Long-term survival after multidisciplinary
management of resected pancreatic adeno-
carcinoma. Ann Surg Oncol 2009;16:836-
47.
Shaib Y, Davila J, Naumann C, El-Serag 48.
H. The impact of curative intent surgery
on the survival of pancreatic cancer pa-
tients: a U.S. population-based study. Am
J Gastroenterol 2007;102:1377-82.
Tseng JF, Tamm EP, Lee JE, Pisters PW, 49.
Evans DB. Venous resection in pancreatic
cancer surgery. Best Pract Res Clin Gas-
troenterol 2006;20:349-64.
Hernandez JM, Cowgill SM, Al-Saadi 50.
S, et al. CA 19-9 velocity predicts disease-
free survival and overall survival after
pancreatectomy of curative intent. J Gas-
trointest Surg 2009;13:349-53.
Slidell MB, Chang DC, Cameron JL, et 51.
al. Impact of total lymph node count and
lymph node ratio on staging and survival
after pancreatectomy for pancreatic ade-
nocarcinoma: a large, population-based
analysis. Ann Surg Oncol 2008;15:165-74.
Pausawasdi N, Scheiman J. Endoscop- 52.
ic evaluation and palliation of pancreatic
adenocarcinoma: current and future op-
tions. Curr Opin Gastroenterol 2007;23:
515-21.
Neoptolemos JP, Stocken DD, Friess H, 53.
et al. A randomized trial of chemoradio-
therapy and chemotherapy after resection
of pancreatic cancer. N Engl J Med 2004;
350:1200-10. [Erratum, N Engl J Med
2004;351:726.]
Oettle H, Post S, Neuhaus P, et al. Ad- 54.
juvant chemotherapy with gemcitabine vs
observation in patients undergoing cura-
tive-intent resection of pancreatic cancer:
a randomized controlled trial. JAMA 2007;
297:267-77.
Regine WF, Winter KA, Abrams RA, 55.
et al. Fluorouracil vs gemcitabine chemo-
therapy before and after fluorouracil-
based chemoradiation following resection
of pancreatic adenocarcinoma: a random-
ized controlled trial. JAMA 2008;299:1019-
26. [Erratum, JAMA 2008;299:1902.]
Herman JM, Swartz MJ, Hsu CC, et al. 56.
Analysis of f luorouracil-based adjuvant
chemotherapy and radiation after pancrea-
ticoduodenectomy for ductal adenocarci-
noma of the pancreas: results of a large,
prospectively collected database at the
Johns Hopkins Hospital. J Clin Oncol
2008;26:3503-10.
Raut CP, Tseng JF, Sun CC, et al. Im- 57.
pact of resection status on pattern of fail-
ure and survival after pancreaticoduo-
denectomy for pancreatic adenocarcinoma.
Ann Surg 2007;246:52-60.
Evans DB, Varadhachary GR, Crane 58.
CH, et al. Preoperative gemcitabine-based
chemoradiation for patients with resect-
able adenocarcinoma of the pancreatic
head. J Clin Oncol 2008;26:3496-502.
Katz MH, Pisters PW, Evans DB, et al. 59.
Borderline resectable pancreatic cancer:
the importance of this emerging stage of
disease. J Am Coll Surg 2008;206:833-46.
Huguet F, Andr T, Hammel P, et al. 60.
Impact of chemoradiotherapy after dis-
ease control with chemotherapy in locally
advanced pancreatic adenocarcinoma in
GERCOR phase II and III studies. J Clin
Oncol 2007;25:326-31.
Sultana A, Tudur Smith C, Cunning- 61.
ham D, et al. Systematic review, including
meta-analyses, on the management of
locally advanced pancreatic cancer using
radiation/combined modality therapy. Br J
Cancer 2007;96:1183-90.
Loehrer PJ, Powell ME, Cardenes HR, 62.
et al. A randomized phase III study of
gemcitabine in combination with radia-
tion therapy versus gemcitabine alone in
patients with localized, unresectable pan-
creatic cancer: E4201. J Clin Oncol 2008;
26:Suppl:4506. abstract.
Chauffert B, Mornex F, Bonnetain F, 63.
et al. Phase III trial comparing intensive
induction chemoradiotherapy (60 Gy, in-
fusional 5-FU and intermittent cisplatin)
followed by maintenance gemcitabine with
gemcitabine alone for locally advanced
unresectable pancreatic cancer: definitive
results of the 2000-01 FFCD/SFRO study.
Ann Oncol 2008;19:1592-9.
Burris HA III, Moore MJ, Andersen J, 64.
et al. Improvements in survival and clini-
cal benefit with gemcitabine as first-line
therapy for patients with advanced pan-
creas cancer: a randomized trial. J Clin
Oncol 1997;15:2403-13.
Sultana A, Smith CT, Cunningham D, 65.
Starling N, Neoptolemos JP, Ghaneh P.
Meta-analyses of chemotherapy for locally
advanced and metastatic pancreatic can-
cer. J Clin Oncol 2007;25:2607-15.
Heinemann V, Boeck S, Hinke A, La- 66.
bianca R, Louvet C. Meta-analysis of ran-
domized trials: evaluation of benefit from
gemcitabine-based combination chemo-
therapy applied in advanced pancreatic
cancer. BMC Cancer 2008;8:82.
Moore MJ, Goldstein D, Hamm J, et al. 67.
Erlotinib plus gemcitabine compared with
gemcitabine alone in patients with ad-
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.
Medical Progress
n engl j med 362;17 nejm.org april 29, 2010
1617
vanced pancreatic cancer: a phase III trial
of the National Cancer Institute of Canada
Clinical Trials Group. J Clin Oncol 2007;
25:1960-6.
Cunningham D, Chau I, Stocken DD, 68.
et al. Phase III randomized comparison
of gemcitabine versus gemcitabine plus
capecitabine in patients with advanced
pancreatic cancer. J Clin Oncol 2009;27:
5513-8.
Xiong HQ, Varadhachary GR, Blais JC, 69.
Hess KR, Abbruzzese JL, Wolff RA. Phase
2 trial of oxaliplatin plus capecitabine
(XELOX) as second-line therapy for pa-
tients with advanced pancreatic cancer.
Cancer 2008;113:2046-52.
Kulke MH, Blaszkowsky LS, Ryan DP, 70.
et al. Capecitabine plus erlotinib in gem-
citabine-refractory advanced pancreatic
cancer. J Clin Oncol 2007;25:4787-92.
Tempero M, Plunkett W, Ruiz Van Ha- 71.
peren V, et al. Randomized phase II com-
parison of dose-intense gemcitabine:
thirty-minute infusion and fixed dose
rate infusion in patients with pancreatic
adenocarcinoma. J Clin Oncol 2003;21:
3402-8.
Louvet C, Labianca R, Hammel P, et al. 72.
Gemcitabine in combination with oxali-
platin compared with gemcitabine alone in
locally advanced or metastatic pancreatic
cancer: results of a GERCOR and GISCAD
phase III trial. J Clin Oncol 2005;23:3509-
16.
Heinemann V, Quietzsch D, Gieseler F, 73.
et al. Randomized phase III trial of gem-
citabine plus cisplatin compared with
gemcitabine alone in advanced pancreatic
cancer. J Clin Oncol 2006;24:3946-52.
Bernhard J, Dietrich D, Scheithauer W, 74.
et al. Clinical benefit and quality of life in
patients with advanced pancreatic cancer
receiving gemcitabine plus capecitabine
versus gemcitabine alone: a randomized
multicenter phase III clinical trial
SAKK 44/00-CECOG/PAN.1.3.001. J Clin
Oncol 2008;26:3695-701.
Li J, Saif MW. Any progress in the 75.
management of advanced pancreatic can-
cer? Highlights from the 45th ASCO an-
nual meeting, Orlando, FL, USA, May 29-
June 2, 2009. JOP 2009;10:361-5.
Faca VM, Song KS, Wang H, et al. 76.
A mouse to human search for plasma pro-
teome changes associated with pancreatic
tumor development. PLoS Med 2008;5(6):
e123.
Rajeshkumar NV, Tan AC, De Oliveira 77.
E, et al. Antitumor effects and biomarkers
of activity of AZD0530, a Src inhibitor, in
pancreatic cancer. Clin Cancer Res 2009;
15:4138-46.
Hewish M, Chau I, Cunningham D. 78.
Insulin-like growth factor 1 receptor tar-
geted therapeutics: novel compounds and
novel treatment strategies for cancer medi-
cine. Recent Pat Anticancer Drug Discov
2009;4:54-72.
Derosier LC, Vickers SM, Zinn KR, et al. 79.
TRA-8 anti-DR5 monoclonal antibody and
gemcitabine induce apoptosis and inhibit
radiologically validated orthotopic pan-
creatic tumor growth. Mol Cancer Ther
2007;6:3198-207.
Gold DV, Schutsky K, Modrak D, Car- 80.
dillo TM. Low-dose radioimmunotherapy
((90)Y-PAM4) combined with gemcitabine
for the treatment of experimental pancre-
atic cancer. Clin Cancer Res 2003;9:3929S-
3937S.
Chung EJ, Brown AP, Asano H, et al. 81.
In vitro and in vivo radiosensitization with
AZD6244 (ARRY-142886), an inhibitor of
mitogen-activated protein kinase/extracel-
lular signal-regulated kinase 1/2 kinase.
Clin Cancer Res 2009;15:3050-7.
Haklai R, Elad-Sfadia G, Egozi Y, 82.
Kloog Y. Orally administered FTS (salira-
sib) inhibits human pancreatic tumor
growth in nude mice. Cancer Chemother
Pharmacol 2008;61:89-96.
Wente MN, Jain A, Kono E, et al. Pros- 83.
tate stem cell antigen is a putative target
for immunotherapy in pancreatic cancer.
Pancreas 2005;31:119-25.
Hassan R, Ebel W, Routhier EL, et al. 84.
Preclinical evaluation of MORAb-009, a
chimeric antibody targeting tumor-asso-
ciated mesothelin. Cancer Immun 2007;
7:20.
Murugesan SR, King CR, Osborn R, et 85.
al. Combination of human tumor necro-
sis factor-alpha (hTNF-alpha) gene deliv-
ery with gemcitabine is effective in mod-
els of pancreatic cancer. Cancer Gene Ther
2009;16:841-7.
Rubio-Viqueira B, Hidalgo M. Direct in 86.
vivo xenograft tumor model for predicting
chemotherapeutic drug response in can-
cer patients. Clin Pharmacol Ther 2009;85:
217-21.
Farrell JJ, Elsaleh H, Garcia M, et al. 87.
Human equilibrative nucleoside trans-
porter 1 levels predict response to gemcit-
abine in patients with pancreatic cancer.
Gastroenterology 2009;136:187-95.
Copyright 2010 Massachusetts Medical Society.
IMAGES IN CLINICAL MEDICINE
The Journal welcomes consideration of new submissions for Images in Clinical
Medicine. Instructions for authors and procedures for submissions can be found
on the Journals Web site at NEJM.org. At the discretion of the editor, images that
are accepted for publication may appear in the print version of the Journal,
the electronic version, or both.
The New England Journal of Medicine
Downloaded from nejm.org on July 3, 2014. For personal use only. No other uses without permission.
Copyright 2010 Massachusetts Medical Society. All rights reserved.